“In the last year, problems in reproducing academic research have drawn a lot of public attention, particularly in the context of translating research into medical advances. Recent studies indicate that up to 70% of research from academic labs cannot be reproduced, representing an enormous waste of money and effort,” said Dr. Elizabeth Iorns, Science Exchange’s co-founder and CEO. “In my experience as a researcher, I found that the problem lay primarily in the lack of incentives and opportunities for validation—the Reproducibility Initiative directly tackles these missing pieces.”
The Reproducibility Initiative provides both a mechanism for scientists to independently replicate their findings and a reward for doing so. Scientists who apply to have their studies replicated are matched with experimental service providers based on the expertise required. The Initiative leverages Science Exchange’s existing marketplace for scientific services, which contains a network of over 1000 expert providers at core facilities and contract research organizations (CROs). “Core facilities and commercial scientific service providers are the solution to this problem,” said Dr. Iorns. “They are experts at specific experimental techniques, and operate outside the current academic incentive structure.”
See related Reuters article here, which highlights the issue of why there is a need for research validation:
"Last year, Bayer Healthcare reported that its scientists could not reproduce some 75 percent of published findings in cardiovascular disease, cancer and women's health.
In March, Lee Ellis of M.D. Anderson Cancer Center and C. Glenn Begley, the former head of global cancer research at Amgen, reported that when the company's scientists tried to replicate 53 prominent studies in basic cancer biology, hoping to build on them for drug discovery, they were able to confirm the results of only six."
Hiç yorum yok:
Yorum Gönder